Back to News
Feb 23, 2026 12:40 PM

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Monday following the company’s announcement of significant revenue growth.

• ImmunityBio stock is challenging resistance. Why are IBRX shares at highs?

The stock has jumped around 55% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.

The company’s lead drug, Anktiva, is approved in the U.S. and several international markets for BCG-unresponsive NMIBC with carcinoma in situ.

700% Sales Jump

ImmunityBio reported a remarkable year-over-year increase in revenue, driven by the sales of Anktiva, which has received regulatory approvals across 33 countries for treating non-muscle invasive bladder cancer.

ImmunityBio reported a fourth-quarter loss of six cents per share compared to the consensus of a loss of nine cents.

Sales jumped from $7.56 million to $38.29 million, beating the consensus of $37.02 million.

The ...